All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Marion SubkleweDuring the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Marion Subklewe, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Will CAR T-cell therapy change the treatment landscape for MCL?
Will CAR T-cell therapy change the treatment landscape for MCL?
The current standard of care for young, fit patients with mantle cell lymphoma (MCL) is chemotherapy-based induction regimens followed by autologous stem cell transplantation (auto-SCT) for consolidation. In patients with relapsed/refractory (R/R) MCL, second-line treatment involves Bruton's tyrosine kinase inhibitors, such as ibrutinib/acalabrutinib.
There is a subset of R/R patients with high-risk disease that has an overall survival of less than 4 years, and this group is the target for testing treatment with CAR T-cells. Marion Subklewe discusses the results of the ZUMA-2 trial evaluating anti-CD19 CAR T-cells in this subset of patients with R/R MCL.
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?